The natural killer T cell ligand α-galactosylceramide prevents or promotes pristane-induced lupus in mice

European Journal of Immunology

Volumn 35, Issue 4, 2005, Pages 1143-1154

  Singh, Avneesh K ^a   Yang, Jun Qi ^b   Parekh, Vrajesh V ^a   Wei, Jie ^a   Wang, Chyung Ru ^c   Joyce, Sebastian ^a   Singh, Ram R ^b,d   Van Kaer, Luc ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CD1d; Glycolipids; Immunotherapy; NKT cells; Systemic lupus erythematosus

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; AUTOANTIBODY; CD1D ANTIGEN; CELL NUCLEUS ANTIGEN; INTERLEUKIN 4; LIGAND; PRISTANE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE EXACERBATION; FEMALE; IN VIVO STUDY; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE ACTIVATION; MOUSE; MOUSE STRAIN; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; SYSTEMIC LUPUS ERYTHEMATOSUS; TH1 CELL; TH2 CELL;

ANIMALS; DISEASE MODELS, ANIMAL; GALACTOSYLCERAMIDES; IMMUNOSUPPRESSIVE AGENTS; KILLER CELLS, NATURAL; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, INBRED BALB C; TERPENES;

EID: 17444420728     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/eji.200425861     Document Type: Article

References (37)

1. Kotzin, B. L., Systemic lupus erythematosus. Cell 1996. 85: 303-306.
2. Kronenberg, M. and Gapin, L., The unconventional lifestyle of NKT cells. Nat. Rev. Immunol. 2002. 2: 557-568.
3. Taniguchi, M., Harada, M., Kojo, S., Nakayama, T. and Wakao, H., The regulatory role of Vα14 NKT cells in innate and acquired immune response. Annu. Rev. Immunol. 2003. 21: 483-513.
4. Godfrey, D. I., MacDonald, H. R., Kronenberg, M., Smyth, M. J. and Van Kaer, L., NKT cells: what's in a name? Nat. Rev. Immunol. 2004. 4: 231-237.
5. Van Kaer, L., Regulation of immune responses by CD1d-restricted natural killer T cells. Immunol. Res. 2004. 30: 139-153.
6. + NK T cells associated with disease development in autoimmune-prone mice. J. Immunol. 1996. 156: 4035-4040.
7. Yang, J.-Q., Saxena, V., Xu, H., Van Kaer, L., Wang, C. R. and Singh, R. R., Repeated α-galactosylceramide administration results in expansion of Vα14 NKT cells and alleviates inflammatory dermatitis in MRL-lpr/lpr mice. J. Immunol. 2003. 171: 4439-4446.
8. + double-negative regulatory natural killer T cells in autoimmune diseases. Arthritis Rheum. 2001. 44: 1127-1138.
9. Oishi, Y., Sumida, T., Sakamoto, A., Kita, Y., Kurasawa, K., Nawata, Y., Takabayashi, K., Takahashi, H., Yoshida, S., Taniguchi, M. et al., Selective reduction and recovery of invariant Vα24JαQ T cell receptor T cells in correlation with disease activity in patients with systemic lupus erythematosus. J. Rheumatol. 2001. 28: 275-283.
10. + NKT cell numbers are decreased in a wide variety of diseases that are characterized by autoreactive tissue damage. Clin. Immunol. 2001. 100: 144-148.
11. Funauchi, M., Yu, H., Sugiyama, M., Ikoma, S., Ohno, M., Kinoshita, K., Hamada, K. and Kanamaru, A., Increased interleukin-4 production by NK T cells in systemic lupus erythematosus. Clin. Immunol. 1999. 92: 197-202.
12. Singh, N., Hong, S., Scherer, D. C., Serizawa, I., Burdin, N., Kronenberg, M., Koezuka, Y. and Van Kaer, L., Cutting edge: activation of NK T cells by CD1d and α-galactosylceramide directs conventional T cells to the acquisition of a Th2 phenotype. J. Immunol. 1999. 163: 2373-2377.
13. Burdin, N., Brossay, L. and Kronenberg, M., Immunization with α-galactosylceramide polarizes CD1-reactive NK T cells towards Th2 cytokine synthesis. Eur. J. Immunol. 1999. 29: 2014-2025.
14. Van Kaer, L., Natural killer T cells as targets for immunotherapy of autoimmune diseases. Immunol. Cell Biol. 2004. 82: 315-322.
15. Zeng, D., Liu, Y., Sidobre, S., Kronenberg, M. and Strober, S., Activation of natural killer T cells in NZB/W mice induces Th1-type immune responses exacerbating lupus. J. Clin. Invest. 2003. 112: 1211-1222.
16. Satoh, M. and Reeves, W. H., Induction of lupus-associated autoantibodies in BALB/c mice by intraperitoneal injection of pristane. J. Exp. Med. 1994. 180: 2341-2346.
17. Satoh, M., Richards, H. B., Shaheen, V. M., Yoshida, H., Shaw, M., Naim, J. O., Wooley, P. H. and Reeves, W. H., Widespread susceptibility among inbred mouse strains to the induction of lupus autoantibodies by pristane. Clin. Exp. Immunol. 2000. 121: 399-405.
18. Yang, J. Q., Singh, A. K., Wilson, M. T., Satoh, M., Stanic, A. K., Park, J. J., Hong, S., Gadola, S. D., Mizutani, A., Kakumanu, S. R. et al., Immunoregulatory role of CD1d in the hydrocarbon oil-induced model of lupus nephritis. J. Immunol. 2003. 171: 2142-2153.
19. + T cells that promptly produce interleukin 4. Proc. Natl. Acad. Sci. USA 1995. 92: 11931-11934.
20. Singh, A. K., Wilson, M. T., Hong, S., Olivares-Villagomez, D., Du, C., Stanic, A. K., Joyce, S., Sriram, S., Koezuka, Y. and Van Kaer, L., Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis. J. Exp. Med. 2001. 194: 1801-1811.
21. Hong, S., Wilson, M. T., Serizawa, I., Wu, L., Singh, N., Naidenko, O. V., Miura, T., Haba, T., Scherer, D. C., Wei, J. et al., The natural killer T cell ligand α-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat. Med. 2001. 7: 1052-1056.
22. Hayakawa, Y., Berzins, S. P., Crowe, N. Y., Godfrey, D. I. and Smyth, M. J., Antigen-induced tolerance by intrathymic modulation of self recognizing inhibitory receptors. Nat. Immunol. 2004. 5: 590-596.
23. Wilson, M. T. and Van Kaer, L., Natural killer T cells as targets for therapeutic intervention in autoimmune diseases. Curr. Pharm. Des. 2003. 9: 201-220.
24. Wallace, D. J., The clinical presentation of systemic lupus erythematosus. In Wallace, D. J. and Hahn, B. H. (Eds.) Dubois' lupus erythematosus, Vol. 6. Lippincott Williams & Wilkins, Philadelphia 2000, pp 621-628.
25. Calvani, N., Satoh, M., Croker, B. P., Reeves, W. H. and Richard, M. F., Nephritogenic autoantibodies but absence of nephritis in IL-12p35-deficient mice with pristane-induced lupus. Kidney Int. 2003. 64: 897-905.
26. Richards, H. B., Satoh, M., Shaw, M., Libert, C., Poli, V. and Reeves, W. H., Interleukin 6 dependence of anti-DNA antibody production: evidence for two pathways of autoantibody formation in pristane-induced lupus. J. Exp. Med. 1998. 188: 985-990.
27. Richards, H. B., Satoh, M., Jennette, J. C., Croker, B. P., Yoshida, H. and Reeves, W. H., Interferon-γ is required for lupus nephritis in mice treated with the hydrocarbon oil pristane. Kidney Int. 2001. 60: 2173-2180.
28. Singh, R. R., Saxena, V., Zang, S., Li, L., Finkelman, F. D., Witte, D. P. and Jacob, C. O., Differential contribution of IL-4 and STAT6 vs STAT4 to the development of lupus nephritis. J. Immunol. 2003. 170: 4818-4825.
29. Waters, S. T., McDuffie, M., Bagavant, H., Deshmukh, U. S., Gaskin, F., Jiang, C., Tung, K. S. and Fu, S. M., Breaking tolerance to double stranded DNA, nucleosome, and other nuclear antigens is not required for the pathogenesis of lupus glomerulonephritis. J. Exp. Med. 2004. 199: 255-264.
30. Ramanujam, M., Wang, X., Huang, W., Schiffer, L., Grimaldi, C., Akkerman, A., Diamond, B., Madaio, M. P. and Davidson, A., Mechanism of action of transmembrane activator and calcium modulator ligand interactor-Ig in murine systemic lupus erythematosus. J. Immunol. 2004. 173: 3524-3534.
31. Yang, J. Q., Chun, T., Liu, H., Hong, S., Bui, H., Van Kaer, L., Wang, C. R. and Singh, R. R., CD1d deficiency exacerbates inflammatory dermatitis in MRL-lpr/lpr mice. Eur. J. Immunol. 2004. 34: 1723-1732.
32. Van Kaer, L., α-Galactosylceramide therapy for autoimmune diseases: prospects and obstacles. Nat. Rev. Immunol. 2005. 5: 31-42.
33. Morita, M., Motoki, K., Akimoto, K., Natori, T., Sakai, T., Sawa, E., Yamaji, K., Koezuka, Y., Kobayashi, E. and Fukushima, H., Structure-activity relationship of α-galactosylceramides against B16-bearing mice. J. Med. Chem. 1995. 38: 2176-2187.
34. Stanic, A. K., De Silva, A. D., Park, J. J., Sriram, V., Ichikawa, S., Hirabyashi, Y., Hayakawa, K., Van Kaer, L., Brutkiewicz, R. R. and Joyce, S., Defective presentation of the CD1d1-restricted natural Va14Ja18 NKT lymphocyte antigen caused by β-d-glucosylceramide synthase deficiency. Proc. Natl. Acad. Sci. USA 2003. 100: 1849-1854.
35. Wilson, M. T., Johansson, C., Olivares-Villagomez, D., Singh, A. K., Stanic, A. K., Wang, C. R., Joyce, S., Wick, M. J. and Van Kaer, L., The response of natural killer T cells to glycolipid antigens is characterized by surface receptor down-modulation and expansion. Proc. Natl. Acad. Sci. USA 2003. 100: 10913-10918.
36. Singh, R. R., Kumar, V., Ebling, F. M., Southwood, S., Sette, A., Sercarz, E. E. and Hahn, B. H., T cell determinants from autoantibodies to DNA can upregulate autoimmunity in murine systemic lupus erythematosus. J. Exp. Med. 1995. 181: 2017-2027.
37. Fan, G. C. and Singh, R. R., Vaccination with minigenes encoding V(H)-derived major histocompatibility complex class I-binding epitopes activates cytotoxic T cells that ablate autoantibody-producing B cells and inhibit lupus. J. Exp. Med. 2002. 196: 731-741.